Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crossover study of APHD-012 in subjects with pathological OGTT/prediabetes
2022-003205-29Phase 2Completed
- Sponsor
- Aphaia Pharma
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of APHD-012 in prediabetes (2 arms), sponsored by Aphaia Pharma. Primary endpoint: Change from baseline in OGTT AUC0–2h. Started Nov 2022; status: completed.
02
Drugs
APHD-012
03
Conditions
prediabetes
Beyond the preview
Go deeper on 2022-003205-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003205-29.